OLR1 and head and neck squamous cell carcinoma: The levels of blood circulating LOX-1+PMN-MDSCs may be proposed as non-invasive biomarkers to predict clinical outcomes of (R/M) HNSCC patients developing resistance to immunotherapy, improving patient selection and suggesting novel personalized therapies.